Michael Kronenberg
SubBasepair_Res
Just thought I'd clarify my thesis on current $PDSB trial: New research has made it clear that interferon-y release by T cells in TME is critical for anti-tumor immune response.
Read more
Ribas et al. 2020 shows that melanoma PDLi responders have higher levels of pre-treatment HLA gene expr. in bulk tumor RNA relative to non-responders, with the difference being amplified upon
Read more
Big part of $TRIL future valuation will be solid tumor data. $ALXO ALX148 in a ph1 trial demonstrated 40% ORR in combo w/ PDL1i for checkpoint inhibitor naive HNSCC tumors.
Read more
$ATNM story: Non-targeted high dose radiation followed by bone marrow transplant is a preferred method to treat blood cancers in patients under 55. The success of this therapy relies on
Read more